Skip to content

Prepaid expenses at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s prepaid expenses?
Relay Therapeutics, Inc. (RLAY) reported prepaid expenses of $11.84M in Q1 2026.
How has Relay Therapeutics, Inc.'s prepaid expenses changed year-over-year?
Relay Therapeutics, Inc.'s prepaid expenses decreased by 46.1% year-over-year, from $21.95M to $11.84M.
What is the long-term trend for Relay Therapeutics, Inc.'s prepaid expenses?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s prepaid expenses has grown at a 11.6% compound annual growth rate (CAGR), from $11.47M to $17.79M.